Analyst: Genmab's Darzalex income coming in faster than expected
A Sydbank analyst following the Danish biotech firm is very interested in the accelerating sales of cancer drug Darzalex, which Genmab reported after Q2.
by marketwire, translated by catherine brett
Genmab’s golden egg, Darzalex, contributed more to Genmab’s overall incomes than expected by Sydbank in the second quarter of 2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab beats expectations across the board
For subscribers
Organizational expansion sends Genmab costs soaring
For subscribers
